Brokerages Set argenx SE (NASDAQ:ARGX) Price Target at $687.00

argenx SE (NASDAQ:ARGX) has received a consensus recommendation of “Moderate Buy” from the twenty-three research firms that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, nineteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $687.00.

ARGX has been the subject of several research reports. Robert W. Baird upped their price target on shares of argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 4th. William Blair restated an “outperform” rating on shares of argenx in a report on Friday, February 28th. Guggenheim lifted their price target on argenx from $775.00 to $1,100.00 and gave the company a “buy” rating in a report on Monday, March 10th. JMP Securities boosted their price target on argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research report on Tuesday, January 14th. Finally, Sanford C. Bernstein raised argenx from a “market perform” rating to an “outperform” rating in a research report on Monday, March 17th.

argenx Stock Down 5.9 %

Shares of NASDAQ ARGX opened at $555.11 on Wednesday. argenx has a twelve month low of $352.77 and a twelve month high of $678.21. The firm has a market cap of $33.73 billion, a PE ratio of -630.81 and a beta of 0.60. The business has a fifty day simple moving average of $621.43 and a two-hundred day simple moving average of $602.61.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. On average, research analysts expect that argenx will post 3.13 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Stifel Financial Corp raised its position in argenx by 15.3% during the 3rd quarter. Stifel Financial Corp now owns 8,832 shares of the company’s stock worth $4,788,000 after buying an additional 1,170 shares during the last quarter. Stephens Inc. AR acquired a new stake in shares of argenx in the fourth quarter worth $310,000. Ritholtz Wealth Management raised its holdings in shares of argenx by 85.5% during the fourth quarter. Ritholtz Wealth Management now owns 898 shares of the company’s stock worth $552,000 after purchasing an additional 414 shares during the last quarter. MML Investors Services LLC lifted its position in argenx by 16.9% during the third quarter. MML Investors Services LLC now owns 8,699 shares of the company’s stock valued at $4,715,000 after purchasing an additional 1,255 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new stake in argenx in the third quarter valued at $652,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.